ClinicalTrials.gg
CompletedNCT03291782Updated Dec 19, 2018

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

A Phase 1 interventional study of D-0120 in Gout, sponsored by InventisBio Co., Ltd. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Enrollment
97th of 149
39 · median 74
Started
2017
with 5 others
Phase 1
32 of 164
none open now
Registered
89th of 164
by date

Among the 164 studies in Gout with a site in United States, this one is the 97th largest by enrollment of the 149 interventional ones that give a count, is one of 6 that started in 2017, is one of 32 in phase 1, and was the 89th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

This initial clinical study in the US will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, and sequential cohort study to evaluate the safety, tolerability, PK and PD of D-0120-NA in fasting, healthy volunteers (HVs).

In food effect cohort, subjects will each receive 2 doses of D-0120-NA in an open-label manner; once in the fasted state and once in the fed state.

03

Conditions studied

  • Gout

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be medically documented as healthy and acceptable at physical examination.
  • Subjects serum uric acid level at screening ≥ 4.5 mg/dL.
  • Subjects must have a between 18.0 and 30.0 kg/m2 and a body weight of 50 kg or higher
  • Subjects must have all laboratory parameters within the normal range or considered not by the principal investigator.
  • Subjects must have a normal urinalysis, , or results considered not clinically significant by the principal investigator.
  • Subjects are able to understand the study procedures and risks involved and must provide signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders.
  • Any history or suspicion of kidney stones.
  • Positive for , , and/or .
  • Subjects who have used prescription drugs, over-the-counter drugs, or herbal remedies within 14 days before Day 1 of study medication dosing.
  • Undergone major surgery within 3 months prior to Day 1.
  • Women who are pregnant or breastfeeding.
  • Subjects who received any test article within 5 half-lives or 30 days prior to Day 1 study medication dosing.
  • Subjects who consumed Seville oranges- or grapefruit-containing foods or beverages within 7 days before Day 1 and during the entire study duration.
  • Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    D-0120 Dose 1

    D-0120 Dose 1 Patients will get D-0120 single agent or placebo of matching size during dose escalation

    Drug: D-0120

  • Experimental
    D-0120 Dose 2

    D-0120 Dose 2 Patients will get D-0120 single agent or placebo of matching size during dose escalation

    Drug: D-0120

  • Experimental
    D-0120 Dose 3

    D-0120 Dose 3 Patients will get D-0120 single agent or placebo of matching size during dose escalation

    Drug: D-0120

  • Experimental
    D-0120 Dose 4

    D-0120 Dose 4 Patients will get D-0120 single agent or placebo of matching size during dose escalation

    Drug: D-0120

  • Experimental
    D-0120 Dose 5

    D-0120 Dose 5 Patients will get D-0120 single agent once in the fasted state and once in the fed state.

    Drug: D-0120

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Adverse Events and changes of Laboratory, Electrocardiogram, and Vital Signs

    Time frame: 2 weeks

Secondary outcomes

  1. Pharmacokinetic: area under the plasma concentration versus time curve (AUC)

    AUC: area under the plasma concentration versus time curve for D-0120

    Time frame: Day-1 through 3

  2. Pharmacokinetic: maximum plasma drug concentration (Cmax)

    Cmax: maximum plasma drug concentration of D-0120

    Time frame: Day-1 through 3

  3. Pharmacokinetic: Time to reach the Cmax (Tmax)

    Tmax: Time to reach the Cmax of D-0120

    Time frame: Day-1 through 3

  4. Pharmacokinetic: Apparent terminal half-life (t1/2)

    t1/2: apparent terminal half-life of D-0120

    Time frame: Day-1 through 3

  5. Pharmacokinetic: Apparent oral clearance (CL/F)

    CL/F: Apparent oral clearance of D-0120

    Time frame: Day-1 through 3

  6. Pharmacokinetic: Apparent volume of distribution (Vz/F)

    Vz/F: Apparent volume of distribution of D-0120

    Time frame: Day-1 through 3

  7. PD profile of D-0120 from plasma and urine

    Profile in terms of Serum uric acid and creatinine; Urine uric acid and creatinine. These parameters will be combined to report fractional excretion of uric acid (FEUa %)

    Time frame: Day-1 through 3

07

Study locations

1 site
  • Covance Daytona Beach Clinical Research Unit
    Daytona Beach, Florida 32117, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Apr 2018, 6 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 6 months is close to that.

Counting every sponsor, half of 41 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2017
First posted
Sep 25, 2017
StartActual
Sep 13, 2017
Primary completionActual
Apr 6, 2018
CompletionActual
Aug 6, 2018
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03291782
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Sep 13, 2017
Primary completion
Apr 6, 2018
Completion
Aug 6, 2018
Last update
Dec 19, 2018

Study contacts

Hugh Coleman, MD
principal investigator · Covance

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-0120

Start the discussion